Vsee Health, INC 8-K filings

VSEE Health, Inc. has received a delisting determination from Nasdaq due to its persistent low stock bid price, with trading suspension set for August 6, 2026.

VSEE Health, Inc. has entered into a settlement agreement to resolve disputes with ADI Funding LLC and M2B Funding Corp., involving repayment of existing debt, issuance of new promissory notes, and restricted shares.

VSee Health, Inc. has announced its 2026 Annual Meeting of Stockholders will be held on August 25, 2026, with July 6, 2026, set as the record date.

VSEE Health, Inc. has entered into two separate agreements to issue convertible notes totaling $575,550, providing capital for general working purposes.

VSee Health, Inc. has received a notice of default from ADI Funding, LLC regarding a $271,739.13 secured promissory note.

VSee Health, Inc. has entered into a securities purchase agreement to issue a secured promissory note to an institutional investor, ADI Funding LLC, for $271,739.13.

VSee Health, Inc. has entered into a Standby Equity Purchase Agreement with YA II PN, LTD. for up to $10 million in common stock.

VSee Health, Inc. has completed the divestiture of its subsidiary, VSee Lab, Inc., to co-CEO Milton Chen in exchange for the cancellation of 2,870,069 shares of company common stock.

VSee Health, Inc. stockholders approved the issuance of common stock to warrant holders at a special meeting held on March 2, 2026.

VSee Health, Inc. announced a strategic investment of $2.0 million for a 10% stake in digital prescription platform GoMyRx, alongside a managed services agreement.

VSee Health, Inc. announced the results of its annual meeting, where stockholders elected two Class I directors and approved the 2025 Equity Incentive Plan.

VSee Health, Inc. announced an amendment to its bylaws, reducing the quorum requirement for stockholder meetings to one-third of voting power, effective December 17, 2025.

VSee Health, Inc. announced the postponement of its 2025 Annual Meeting of Stockholders to December 30, 2025, citing an anticipated lack of quorum.

VSee Health, Inc. has designated up to 2,000 shares of Series B Convertible Preferred Stock with a $1,000 stated value, establishing new terms for capital structure.

VSee Health, Inc. announced an amendment to its 8-K filing, detailing transactions that boosted its pro forma stockholders' equity to $9.5 million, ensuring compliance with Nasdaq listing requirements.

VSEE Health, Inc. announced it has achieved pro forma compliance with Nasdaq's minimum stockholders' equity requirement, averting a potential delisting.

VSee Health, Inc. announced a private placement of common stock, pre-funded warrants, and common warrants, raising approximately $6 million for working capital.

VSee Health, Inc. has secured $201,000 in financing through a convertible promissory note and the issuance of 50,000 shares of common stock to an institutional investor.

VSee Health, Inc. announced an exchange of a $611,878 promissory note for common stock and established a $25 million equity line of credit with an institutional investor.

VSee Health, Inc. entered into an agreement with an institutional investor to exchange 2.25 million warrants for 2.175 million common shares and exercise an additional 130,000 warrants for cash.

VSee Health, Inc. announced the date for its 2025 annual stockholders meeting and key deadlines for stockholder proposals.

VSee Health, Inc. has amended its senior secured convertible promissory note, revising the conversion price to $0.75 per share.

VSee Health, Inc. has secured a $133,333.33 senior secured promissory note from Ascent Partners Fund LLC for working capital, maturing in May 2026.

VSee Health, Inc. has dismissed its independent registered public accounting firm, WithumSmith+Brown, PC, and appointed WWC, P.C., following a prior 'going concern' explanatory paragraph and material weaknesses.

VSee Health, Inc. has entered into a Note Purchase Agreement with Ascent Partners Fund LLC, issuing a $133,333.33 Senior Secured Promissory Note for $120,000, due May 2026.

VSee Health, Inc. received a Nasdaq deficiency letter due to its common stock trading below $1.00, failure to file quarterly reports, and insufficient stockholders' equity.

VSee Health, Inc. received an additional Nasdaq delisting notice due to falling below the minimum stockholders' equity requirement, compounding prior non-compliance issues.

VSee Health, Inc. announced it will restate multiple prior financial statements due to a series of accounting errors, impacting reports from 2023 and 2024.

VSee Health received an additional Nasdaq delisting notice for failing to file its Q2 2025 quarterly report, compounding prior non-compliance issues.

VSee Health, Inc. received a Nasdaq delisting determination due to delayed financial filings, with trading suspended on August 14, 2025, and plans to appeal.